|
|
|
|
Vol. 58, Issue 4, 821-827, October 2000
2C-Adrenergic
Receptor by cAMP
Institut National de la Santé et de la Recherche
Médicale Unit 388, Institut L. Bugnard, CHU Rangueil, Toulouse,
France (S.S., C.C., D.C., C.D., H.P.); and Department of Pharmacology,
School of Medicine, University of Patras, Patras, Greece (A.L., C.F.)
The heterologous regulation of the
2C-adrenergic receptor (
2C-AR)
was investigated in the HepG2 cell line. Binding of
[3H]MK912 (
2-antagonist) to membranes from cells
submitted to various treatments showed that exposure to insulin,
phorbol 12-myristate 13-acetate, or dexamethasone did not affect
receptor density. On the other hand, treatment with forskolin resulted
in a large reduction of
2C-AR number. The effect of forskolin was
mimicked by 8-br-cAMP and was abolished by the protein kinase A
inhibitor, H89. The action of cAMP was slow
(t1/2 = 23 h), dose-dependent, and
additive to the receptor down-regulation elicited by the
2-agonist, UK14304. Furthermore, the diminution of receptor was not caused by an
increased rate of its degradation but resulted from a decrease in the
steady state amounts of
2C4-mRNA. As assessed by experiments in the
presence of actinomycin D, the stability of
2C4-mRNA was not
affected by 8-br-cAMP or forskolin. By contrast, the activity of a
luciferase construct containing the entire promoter region of the
2C4 gene (1.9 kilobase pairs) was inhibited, indicating that the
primary mechanism of action of the two compounds is at the
transcriptional level. Deletions in the 5'-end of this construct showed
that the elements responsible for cAMP responsiveness lie within a
242-base-pair fragment of the gene promoter (nucleotides
236/+6
relative to transcription start). Band-shift experiments indicated that
nuclear factors bind to this region in a cAMP-dependent manner. The
determination of the actual cis- and
trans-acting elements involved will be the object of
future investigation, but the present study provides evidence for
transcriptional regulation of human
2C-AR by cAMP.
This article has been cited by other articles:
![]() |
A. H. Eid, M. A. Chotani, S. Mitra, T. J. Miller, and N. A. Flavahan Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle {alpha}2C-adrenoceptors Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H266 - H272. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Desai, K. M. Standifer, and D. C. Eikenburg Cellular G Protein-Coupled Receptor Kinase Levels Regulate Sensitivity of the {alpha}2B-Adrenergic Receptor to Undergo Agonist-Induced Down-Regulation J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 767 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Chotani, S. Mitra, A. H. Eid, S. A. Han, and N. A. Flavahan Distinct cAMP signaling pathways differentially regulate {alpha}2C-adrenoceptor expression: role in serum induction in human arteriolar smooth muscle cells Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H69 - H76. [Abstract] [Full Text] [PDF] |
||||